Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications

Area of Science:

• Biochemistry and Pharmacology
• Medicinal Chemistry
• Drug Discovery

Background:

• Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors regulating diverse physiological processes.
• PPARα, PPARβ/δ, and PPARγ subtypes have distinct roles in lipid and glucose metabolism, energy homeostasis, and inflammation.
• Dysregulation of PPARs is implicated in metabolic disorders, neurodegenerative diseases, and obesity.

Purpose of the Study:

• To review current research and patents on heterocyclic compounds designed as PPAR ligands.
• To compile structure-activity relationships (SAR) and mechanistic insights for novel PPAR agonists.
• To guide the design and development of new therapeutic agents targeting PPARs.

Main Methods:

• Synthesis and evaluation of various heterocyclic scaffolds for PPAR agonistic activity.
• Analysis of structure-activity relationships (SAR) to understand compound-receptor interactions.
• In silico docking studies and pharmacological evaluations to elucidate mechanisms of action.

Main Results:

• Numerous heterocyclic compounds have been identified as potential PPAR ligands.
• SAR studies reveal key interactions, including hydrogen bonding and hydrophobic forces, that determine ligand potency.
• Pharmacological and in silico data provide mechanistic understanding of these interactions.

Conclusions:

• Heterocyclic scaffolds represent a promising chemical space for developing novel PPAR-targeting drugs.
• Understanding SAR and molecular interactions is crucial for optimizing PPAR ligand design.
• These findings facilitate the development of new therapeutics for a range of diseases.